Clinical Trials
Myrtle
A Phase 1b open-label, randomized, single dose and repeat dose study to evaluate the single and repeat dose safety and tolerability of intravitreally administered PYC-001 in participants with confirmed OPA1 mutation-associated autosomal dominant optic atrophy.
Overview
A Phase 1b open-label, randomized, single dose and repeat dose study to evaluate the single and repeat dose safety and tolerability of intravitreally administered PYC-001 in participants with confirmed OPA1 mutation-associated autosomal dominant optic atrophy.
- Principal Investigator
Dr Doron Hickey
A Phase 1b open-label, randomized, single dose and repeat dose study to evaluate the single and repeat dose safety and tolerability of intravitreally administered PYC-001 in participants with confirmed OPA1 mutation-associated autosomal dominant optic atrophy.
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.